NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

including demonstration of target engagement and safety in non-human primates, exhibiting strong biodistribution for our lead program in neuromuscular disorders. We believe that CRISPR-GNDM has huge ...

The work, led by Broad senior group leaders Sonia Vallabh and Eric Minikel, as well as Broad core institute member David Liu, is the first demonstration ... development of CRISPR-Cas9 gene editing ...

The work, led by Broad senior group leaders Sonia Vallabh and Eric Minikel, as well as Broad core institute member David Liu, is the first demonstration ... development of CRISPR-Cas9 gene editing ...

Akadeum Life Sciences®' successful early access program for the Aleriontm Microbubble Cell Separation System confirmed the Aleriontm to be the highest capacity, fastest, most gentle cell isolation ...

Therap Services, the national leader in providing HIPAA-compliant electronic documentation solutions to organizations in the Long-Term Services and Supports (LTSS), Home and Community-Based Services ...

This paper presents methodologies based on genetic engineering, like the CRISPR/Cas9 system ... of our knowledge in the field of regenerative medicine, since the demonstration that adult and ...

The FRT scholar will engineer CRISPR proteins and test for a specific application ... Medicine in autoimmune disease ^ This project involves identification and demonstration of gene variants ...

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day. ZUG, Switzerland and BOSTON, Jan. 29, 2025 (GLOBE ...

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...